Results from the phase 3 PEACE-3 study found that a combination therapy showed higher benefits for patients with bone ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Preliminary efficacy assessment from cohort 4 showed that all 3 participants had reductions in prostate-specific antigen (PSA) levels following 2 doses of 12GBq of 67 Cu-SAR-bisPSMA, with the largest ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Survival after moderate HFRT in patients with high-risk prostate cancer was a secondary outcome of the randomized phase 3 Prostate Cancer Study 5 trial.

Nonlinear association seen for effective castration period with metastasis-free survival for any ADT duration.

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

Berlin: Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as ...

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...